RxDoctor Payments Data

Iyad Isseh

Advanced Heart Failure and Transplant Cardiology · Falls Church, VANPI 1780002295

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (40.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Abbott accounts for 64.7% of it on its own, with 6 other manufacturers making up the rest.

$6,187in general payments, 2019–2025

Across 49 payments — averaging $126.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Maquet Cardiovascular L.L.C.$2K
  • Abiomed$148
  • Getinge USA Sales, LLC$98
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$76
  • United Therapeutics Corporation$26
  • plus $18 from 1 others
$189,473in research payments, 2019–2025

Across 13 payments — averaging $14,575 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$187K
  • Organon$3K

What the payments were for

  • Consulting fees$1,82029%
  • Travel & lodging$2,47540%
  • Food & beverage$1,89231%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,187 in reported general payments places this provider in the 55th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.

See all advanced heart failure and transplant cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$45,479
Medicare patients
120
Services billed
320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis32$1,143,935
EntrestoSacubitril/Valsartan35$56,688
JardianceEmpagliflozin13$21,847
FarxigaDapagliflozin Propanediol14$14,155
Eplerenone16$496
Metoprolol Succinate41$386
Carvedilol24$346
Warfarin Sodium22$329
Spironolactone38$302

Paid to pharmacies, not to this prescriber.

Other advanced heart failure and transplant cardiology in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →